HES1 in immunity and cancer

Aradhana Rani; Roseanna Greenlaw; Richard A Smith; Christine Galustian

doi:10.1016/j.cytogfr.2016.03.010

HES1 in immunity and cancer

Aradhana Rani, Roseanna Greenlaw, Richard A Smith, Christine Galustian

King's College London

Research output: Contribution to journal › Article › peer-review

61 Citations (Scopus)

404 Downloads (Pure)

Abstract

Abstract Hairy and enhancer of split homolog-1 (HES1) is a part of an extensive family of basic helix-loop-helix (bHLH) proteins and plays a crucial role in the control and regulation of cell cycle, proliferation, cell differentiation, survival and apoptosis in neuronal, endocrine, T-lymphocyte progenitors as well as various cancers. HES1 is a transcription factor which is regulated by the NOTCH, Hedgehog and Wnt signalling pathways. Aberrant expression of these pathways is a common feature of cancerous cells. There appears to be a fine and complicated crosstalk at the molecular level between the various signalling pathways and HES1, which contributes to its effects on the immune response and cancers such as leukaemia. Several mechanisms have been proposed, including an enhanced invasiveness and metastasis by inducing epithelial mesenchymal transition (EMT), in addition to its strict requirement for tumour cell survival. In this review, we summarize the current biology and molecular mechanisms as well as its use as a clinical target in cancer therapeutics.

Original language	English
Journal	Cytokine and Growth Factor Reviews
Early online date	19 Mar 2016
DOIs	https://doi.org/10.1016/j.cytogfr.2016.03.010
Publication status	E-pub ahead of print - 19 Mar 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cytogfr.2016.03.010

1-s2.0-S1359610116300314-mainAccepted author manuscript, 1.4 MBLicence: CC BY-NC-ND

Cite this

@article{cc621c36cc6446829041f1d8436e11b5,

title = "HES1 in immunity and cancer",

abstract = "Abstract Hairy and enhancer of split homolog-1 (HES1) is a part of an extensive family of basic helix-loop-helix (bHLH) proteins and plays a crucial role in the control and regulation of cell cycle, proliferation, cell differentiation, survival and apoptosis in neuronal, endocrine, T-lymphocyte progenitors as well as various cancers. HES1 is a transcription factor which is regulated by the NOTCH, Hedgehog and Wnt signalling pathways. Aberrant expression of these pathways is a common feature of cancerous cells. There appears to be a fine and complicated crosstalk at the molecular level between the various signalling pathways and HES1, which contributes to its effects on the immune response and cancers such as leukaemia. Several mechanisms have been proposed, including an enhanced invasiveness and metastasis by inducing epithelial mesenchymal transition (EMT), in addition to its strict requirement for tumour cell survival. In this review, we summarize the current biology and molecular mechanisms as well as its use as a clinical target in cancer therapeutics.",

author = "Aradhana Rani and Roseanna Greenlaw and Smith, {Richard A} and Christine Galustian",

year = "2016",

month = mar,

day = "19",

doi = "10.1016/j.cytogfr.2016.03.010",

language = "English",

journal = "Cytokine and Growth Factor Reviews",

issn = "1359-6101",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - HES1 in immunity and cancer

AU - Rani, Aradhana

AU - Greenlaw, Roseanna

AU - Smith, Richard A

AU - Galustian, Christine

PY - 2016/3/19

Y1 - 2016/3/19

N2 - Abstract Hairy and enhancer of split homolog-1 (HES1) is a part of an extensive family of basic helix-loop-helix (bHLH) proteins and plays a crucial role in the control and regulation of cell cycle, proliferation, cell differentiation, survival and apoptosis in neuronal, endocrine, T-lymphocyte progenitors as well as various cancers. HES1 is a transcription factor which is regulated by the NOTCH, Hedgehog and Wnt signalling pathways. Aberrant expression of these pathways is a common feature of cancerous cells. There appears to be a fine and complicated crosstalk at the molecular level between the various signalling pathways and HES1, which contributes to its effects on the immune response and cancers such as leukaemia. Several mechanisms have been proposed, including an enhanced invasiveness and metastasis by inducing epithelial mesenchymal transition (EMT), in addition to its strict requirement for tumour cell survival. In this review, we summarize the current biology and molecular mechanisms as well as its use as a clinical target in cancer therapeutics.

AB - Abstract Hairy and enhancer of split homolog-1 (HES1) is a part of an extensive family of basic helix-loop-helix (bHLH) proteins and plays a crucial role in the control and regulation of cell cycle, proliferation, cell differentiation, survival and apoptosis in neuronal, endocrine, T-lymphocyte progenitors as well as various cancers. HES1 is a transcription factor which is regulated by the NOTCH, Hedgehog and Wnt signalling pathways. Aberrant expression of these pathways is a common feature of cancerous cells. There appears to be a fine and complicated crosstalk at the molecular level between the various signalling pathways and HES1, which contributes to its effects on the immune response and cancers such as leukaemia. Several mechanisms have been proposed, including an enhanced invasiveness and metastasis by inducing epithelial mesenchymal transition (EMT), in addition to its strict requirement for tumour cell survival. In this review, we summarize the current biology and molecular mechanisms as well as its use as a clinical target in cancer therapeutics.

U2 - 10.1016/j.cytogfr.2016.03.010

DO - 10.1016/j.cytogfr.2016.03.010

M3 - Article

SN - 1359-6101

JO - Cytokine and Growth Factor Reviews

JF - Cytokine and Growth Factor Reviews

ER -

HES1 in immunity and cancer

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this